(CTNM) Contineum Therapeutics - Ratings and Ratios
CNS,Pain,Inflammation
Description: CTNM Contineum Therapeutics August 16, 2025
Contineum Therapeutics, Inc. is a pharmaceutical company listed on NASDAQ under the ticker symbol CTNM. The companys stock is classified as a common stock, and it is based in the United States. As a player in the pharmaceuticals industry, Contineum Therapeutics is likely involved in the development, manufacturing, and distribution of therapeutic treatments.
The companys quarterly tax provision data suggests that it is operating at a loss, as indicated by the negative Return on Equity (RoE) of -29.75%. This is not uncommon for pharmaceutical companies, which often invest heavily in research and development (R&D) and may not generate profits until their products are approved and commercialized. Key drivers of the companys stock performance may include R&D milestones, regulatory approvals, and partnerships or collaborations.
To evaluate the companys potential, investors may consider key performance indicators (KPIs) such as R&D expenses as a percentage of revenue, pipeline development progress, and cash burn rate. The companys market capitalization of $174.12 million suggests that it is a relatively small-cap stock, which may be associated with higher volatility and potential for growth. The absence of a reported P/E ratio and forward P/E ratio further supports the notion that the company is not yet profitable.
From a trading perspective, the stocks price movement and volatility may be influenced by factors such as average trading volume, short interest, and institutional ownership. With an average volume of 183,100 shares, the stock appears to have a relatively moderate level of liquidity. Investors may also consider the stocks beta, although it is not reported in this case. A more detailed analysis of the companys financials, management team, and industry trends would be necessary to form a comprehensive view of its investment potential.
CTNM Stock Overview
| Market Cap in USD | 321m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2024-04-05 |
CTNM Stock Ratings
| Growth Rating | -63.6% |
| Fundamental | 30.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -47.1% |
| Analyst Rating | 4.60 of 5 |
CTNM Dividends
Currently no dividends paidCTNM Growth Ratios
| Growth Correlation 3m | 40.8% |
| Growth Correlation 12m | -31.4% |
| Growth Correlation 5y | -73.6% |
| CAGR 5y | -23.64% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.28 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.58 |
| Sharpe Ratio 12m | -1.60 |
| Alpha | -44.55 |
| Beta | |
| Volatility | 63.83% |
| Current Volume | 117k |
| Average Volume 20d | 92.9k |
| Stop Loss | 9.7 (-7.1%) |
| Signal | -0.91 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-59.4m TTM) > 0 and > 6% of Revenue (6% = 14.5k TTM) |
| FCFTA -0.28 (>2.0%) and ΔFCFTA -11.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 73.8k% (prev 418.7%; Δ 73.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -52.5m > Net Income -59.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 29.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.1m) change vs 12m ago 9.27% (target <= -2.0% for YES) |
| Gross Margin 17.36% (prev 99.68%; Δ -82.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.12% (prev 23.14%; Δ -23.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.56 (EBITDA TTM -63.4m / Interest Expense TTM 10.7m) >= 6 (WARN >= 3) |
Altman Z'' -14.63
| (A) 0.94 = (Total Current Assets 184.9m - Total Current Liabilities 6.36m) / Total Assets 190.8m |
| (B) -0.85 = Retained Earnings (Balance) -162.2m / Total Assets 190.8m |
| (C) -0.24 = EBIT TTM -48.7m / Avg Total Assets 203.4m |
| (D) -15.60 = Book Value of Equity -161.9m / Total Liabilities 10.4m |
| Total Rating: -14.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.57
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -36.59% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.59 = 2.24 |
| 6. ROIC - WACC (= -32.98)% = -12.50 |
| 7. RoE -32.33% = -2.50 |
| 8. Rev. Trend -28.55% = -2.14 |
| 9. EPS Trend 59.44% = 2.97 |
What is the price of CTNM shares?
Over the past week, the price has changed by -4.22%, over one month by -5.78%, over three months by +74.00% and over the past year by -37.11%.
Is Contineum Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTNM is around 10.06 USD . This means that CTNM is currently overvalued and has a potential downside of -3.64%.
Is CTNM a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTNM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.8 | 117.9% |
| Analysts Target Price | 22.8 | 117.9% |
| ValueRay Target Price | 11 | 5.7% |
CTNM Fundamental Data Overview November 04, 2025
P/S = 11.147
P/B = 1.7589
Beta = None
Revenue TTM = 242.0k USD
EBIT TTM = -48.7m USD
EBITDA TTM = -63.4m USD
Long Term Debt = 6.26m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 1.48m USD (from shortTermDebt, last quarter)
Debt = 5.49m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -37.1m USD (from netDebt column, last quarter)
Enterprise Value = 144.4m USD (321.3m + Debt 5.49m - CCE 182.4m)
Interest Coverage Ratio = -4.56 (Ebit TTM -48.7m / Interest Expense TTM 10.7m)
FCF Yield = -36.59% (FCF TTM -52.8m / Enterprise Value 144.4m)
FCF Margin = -21.8k% (FCF TTM -52.8m / Revenue TTM 242.0k)
Net Margin = -24.5k% (Net Income TTM -59.4m / Revenue TTM 242.0k)
Gross Margin = 17.36% ((Revenue TTM 242.0k - Cost of Revenue TTM 200.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.76 (Enterprise Value 144.4m / Total Assets 190.8m)
Interest Expense / Debt = 194.3% (Interest Expense 10.7m / Debt 5.49m)
Taxrate = -0.0% (0.0 / -42.3m)
NOPAT = -48.7m (EBIT -48.7m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 29.07 (Total Current Assets 184.9m / Total Current Liabilities 6.36m)
Debt / Equity = 0.03 (Debt 5.49m / totalStockholderEquity, last quarter 180.5m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -37.1m / EBITDA -63.4m)
Debt / FCF = 0.70 (negative FCF - burning cash) (Net Debt -37.1m / FCF TTM -52.8m)
Total Stockholder Equity = 183.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.12% (Net Income -59.4m / Total Assets 190.8m)
RoE = -32.33% (Net Income TTM -59.4m / Total Stockholder Equity 183.7m)
RoCE = -25.65% (EBIT -48.7m / Capital Employed (Equity 183.7m + L.T.Debt 6.26m))
RoIC = -26.37% (negative operating profit) (NOPAT -48.7m / Invested Capital 184.7m)
WACC = 6.61% (E(321.3m)/V(326.8m) * Re(6.72%) + (debt cost/tax rate unavailable))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.77%
Fair Price DCF = unknown (Cash Flow -52.8m)
EPS Correlation: 59.44 | EPS CAGR: 23.97% | SUE: 0.13 | # QB: 0
Revenue Correlation: -28.55 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for CTNM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle